This scoring system allowed for semi-quantitative evaluation of cartilage integrity based on macroscopic features such as softening, fibrillation, erosion, ulceration, and complete cartilage loss [1]
future studies will shed light on whether semaglutide can compete (or synergize) with non-GLP-1 drugs like resmetirom (Madrigal, 30% resolution at 52 weeks), efuxifermin (Akero) and Lanifibranor (Inventiva) that are in late stage clinical testing for NASH
Green tea extracts, particularly compounds like epigallocatechin gallate (EGCG), have demonstrated modest modulating effects in research
Make sure you're hitting adequate protein and nutrients - the appetite suppression from semaglutide can make it easy to under-eat protein
Data were pooled using random-effects models, and subgroup analyses were performed by drug type and treatment duration